GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Cyclically Adjusted PB Ratio

SRPT (Sarepta Therapeutics) Cyclically Adjusted PB Ratio : 1.65 (As of Jul. 04, 2025)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-07-04), Sarepta Therapeutics's current share price is $18.24. Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $11.04. Sarepta Therapeutics's Cyclically Adjusted PB Ratio for today is 1.65.

The historical rank and industry rank for Sarepta Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

SRPT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.55   Med: 12.1   Max: 38.73
Current: 1.65

During the past years, Sarepta Therapeutics's highest Cyclically Adjusted PB Ratio was 38.73. The lowest was 1.55. And the median was 12.10.

SRPT's Cyclically Adjusted PB Ratio is ranked worse than
51.25% of 679 companies
in the Biotechnology industry
Industry Median: 1.56 vs SRPT: 1.65

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sarepta Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $11.630. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $11.04 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sarepta Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Cyclically Adjusted PB Ratio Chart

Sarepta Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.15 10.60 13.55 9.55 11.29

Sarepta Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.52 15.13 11.82 11.29 5.78

Competitive Comparison of Sarepta Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Sarepta Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sarepta Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=18.24/11.04
=1.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Sarepta Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=11.63/134.9266*134.9266
=11.630

Current CPI (Mar. 2025) = 134.9266.

Sarepta Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 3.983 100.684 5.338
201509 2.937 100.392 3.947
201512 4.172 99.792 5.641
201603 3.036 100.470 4.077
201606 2.537 101.688 3.366
201609 7.518 101.861 9.958
201612 6.149 101.863 8.145
201703 7.811 102.862 10.246
201706 6.826 103.349 8.912
201709 10.797 104.136 13.989
201712 12.181 104.011 15.802
201803 11.860 105.290 15.198
201806 10.536 106.317 13.371
201809 9.594 106.507 12.154
201812 14.524 105.998 18.488
201903 18.191 107.251 22.885
201906 14.788 108.070 18.463
201909 13.358 108.329 16.638
201912 10.882 108.420 13.542
202003 14.685 108.902 18.194
202006 13.296 108.767 16.494
202009 11.322 109.815 13.911
202012 9.597 109.897 11.783
202103 6.714 111.754 8.106
202106 6.077 114.631 7.153
202109 5.872 115.734 6.846
202112 10.651 117.630 12.217
202203 9.793 121.301 10.893
202206 8.299 125.017 8.957
202209 4.909 125.227 5.289
202212 4.377 125.222 4.716
202303 7.652 127.348 8.107
202306 7.949 128.729 8.332
202309 8.172 129.860 8.491
202312 9.168 129.419 9.558
202403 10.172 131.776 10.415
202406 11.304 132.554 11.506
202409 12.787 133.029 12.969
202412 15.766 133.157 15.976
202503 11.630 134.927 11.630

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sarepta Therapeutics  (NAS:SRPT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sarepta Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics Business Description

Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Executives
Claude Nicaise director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404